Experienced in Rhabdoid Tumor

Dr. Carl R. Gray

Oncology
Layton, UT 
Accepting New Patients
Experienced in Rhabdoid Tumor
Layton, UT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Carl Gray is an Oncologist in Layton, Utah. Dr. Gray is rated as an Experienced provider by MediFind in the treatment of Rhabdoid Tumor. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Breast Cancer, Paget Disease of the Breast, and Lung Cancer. Dr. Gray is currently accepting new patients.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
University Of Texas Medical School At Houston
Residency
University of California Davis Health Program
Specialties
Oncology
Licenses
Internal Medicine in UT
Board Certifications
Internal Medicine-American Board Of Internal Medicine
Medical Oncology-American Board Of Internal Medicine
Hematology-American Board Of Internal Medicine
Fellowships
University of California Davis Health Program
Hospital Affiliations
Layton Hospital
McKay Dee Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BridgeSpan
  • EPO
  • HMO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Deseret Mutual Benefit Administrators
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Regence
  • EPO
  • PPO
SelectHealth
  • HMO
  • POS
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
University of Utah Health
  • EPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Ogden Clinic-Utah Hematology Oncology
Layton, UT 84041

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Niraparib (PARP Inhibitor) Plus Dostarlimab (Anti-PD1) for Small Cell Lung Cancer (SCLC) and Other High-Grade Neuroendocrine Carcinomas (NEC)
Niraparib (PARP Inhibitor) Plus Dostarlimab (Anti-PD1) for Small Cell Lung Cancer (SCLC) and Other High-Grade Neuroendocrine Carcinomas (NEC)
Enrollment Status: Active_not_recruiting
Publish Date: December 15, 2025
Intervention Type: Biological, Drug
Study Drugs: Dostarlimab, Niraparib
Study Phase: Phase 2
A Phase II, Multicenter, Randomized, Open-label Study to Evaluate the Safety and Efficacy of 400 mg of Ribociclib in Combination With Non-steroidal Aromatase Inhibitors for the Treatment of Pre- and Postmenopausal Women With Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease
A Phase II, Multicenter, Randomized, Open-label Study to Evaluate the Safety and Efficacy of 400 mg of Ribociclib in Combination With Non-steroidal Aromatase Inhibitors for the Treatment of Pre- and Postmenopausal Women With Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease
Enrollment Status: Completed
Publish Date: October 16, 2025
Intervention Type: Drug
Study Drugs: Ribociclib, Letrozole or Anastrozole, Goserelin
Study Phase: Phase 2
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 13, 2025
Intervention Type: Drug
Study Drugs: Niraparib, Dostarlimab
Study Phase: Phase 3
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Enrollment Status: Completed
Publish Date: September 01, 2022
Intervention Type: Other
Stool Collection Sub-Study of Exact Sciences Protocol 2018-01: Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Stool Collection Sub-Study of Exact Sciences Protocol 2018-01: Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Enrollment Status: Completed
Publish Date: June 06, 2022
Intervention Type: Other
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Hematologic Malignancies
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Hematologic Malignancies
Enrollment Status: Terminated
Publish Date: February 03, 2021
Intervention Type: Other
View 5 Less Clinical Trials

1 Total Publications

Treatment of pancreatic and periampullary cancers at a community hospital: successful application of tertiary care treatment standards.
Treatment of pancreatic and periampullary cancers at a community hospital: successful application of tertiary care treatment standards.
Journal: International journal of surgical oncology
Published: May 28, 2011
Similar Doctors
Distinguished in Rhabdoid Tumor
Dr. Anna W. Chalmers
Hematology Oncology | Hematology | Oncology
Distinguished in Rhabdoid Tumor
Dr. Anna W. Chalmers
Hematology Oncology | Hematology | Oncology

University Of Utah Adult Services

1950 Circle Of Hope Dr, 
Salt Lake City, UT 
 (27.3 miles away)
801-581-8793
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Anna Chalmers is a Hematologist Oncology specialist and a Hematologist in Salt Lake City, Utah. Dr. Chalmers is rated as a Distinguished provider by MediFind in the treatment of Rhabdoid Tumor. Her top areas of expertise are Adult Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, Liposarcoma, and Synovial Sarcoma. Dr. Chalmers is currently accepting new patients.

Advanced in Rhabdoid Tumor
Dr. Gregory J. Litton
Oncology
Advanced in Rhabdoid Tumor
Dr. Gregory J. Litton
Oncology

UCS Cancer Center- Medical & Radiation Oncology

Salt Lake City, UT 
 (31.6 miles away)
801-269-0231
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Gregory Litton is an Oncologist in Salt Lake City, Utah. Dr. Litton is rated as a Distinguished provider by MediFind in the treatment of Rhabdoid Tumor. His top areas of expertise are Paget Disease of the Breast, Breast Cancer, Non-Hodgkin Lymphoma, and Pleuropulmonary Blastoma. Dr. Litton is currently accepting new patients.

Advanced in Rhabdoid Tumor
Dr. Nathan T. Rich
Oncology
Advanced in Rhabdoid Tumor
Dr. Nathan T. Rich
Oncology

Utah Valley Hospital

Provo, UT 
 (61.4 miles away)
801-357-8200
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Nathan Rich is an Oncologist in Provo, Utah. Dr. Rich is rated as a Distinguished provider by MediFind in the treatment of Rhabdoid Tumor. His top areas of expertise are Thrombotic Thrombocytopenic Purpura, Small Cell Lung Cancer (SCLC), Chronic Lymphocytic Leukemia (CLL), and Paget Disease of the Breast. Dr. Rich is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gray's expertise for a condition
ConditionClose
    View All 14 Distinguished Conditions
    View All 49 Advanced Conditions
    View All 109 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile